HEMGENIX - AN OVERVIEW

Variety of qualified clients: CDEC reviewed the uncertainty in the quantity of clients with reasonably significant to significant hemophilia B in Canada qualified for etranacogene dezaparvovec. Clinical specialists consulted by CADTH indicated that some patients who will be categorised as owning delicate or reasonable illness may have a severe blee